India

LAXAI Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

CSIR Seeks Regulatory Nod for Clinical Trials Using Combination of Antivirals and HDTs Against COVID-19

Lead Product(s): Favipiravir,Colchicine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

Study will combine and repurpose antivirals and host-directed therapies and to determine safety & efficacy of a combination of drugs (Favipiravir+Colchicine, Umifenovir+Colchicine and Nafamostat+5-ALA) and a control arm with the standard of care in COVID-19 patients.

Serum Institute of India

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

India's Serum Institute to Play Pivotal Role in COVID-19 Vaccines

Lead Product(s): VPM1002

Therapeutic Area: Infections and Infectious Diseases Product Name: VPM1002

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

Details:

SII is currently working on three candidates for COVID-19, including the testing of its recombinant-BCG vaccine in Phase 3 clinical trials at several locations across India.

Bharat Serums & Vaccines ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Bharat Serums to assess sepsis drug Ulinastatin for Covid-19

Lead Product(s): Urinastatin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 09, 2020

Details:

The trial will involve approximately 120 patients who have mild to moderate symptoms of acute ARDS. The drug is expected to improve recovery time and also mitigate mortality rates.

Glenmark

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Glenmark to Commence Another New Phase 3 Clinical Trial on a Combination of Two Anti-Viral Drugs Favipiravir and Umifenovir for COVID-19

Lead Product(s): Favipiravir,Umifenovir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 26, 2020

Details:

Early treatment with combination therapy will be evaluated for safety and efficacy as it is emerging as an effective approach in shortening duration of virus shedding, decreasing cytokine response, and facilitating early discharge of patients.

NovaLead Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Novalead to Start Trial on Anti- Parasitic Drug for Covid-19

Lead Product(s): Nitazoxanide

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2020

Details:

Novalead will study the effectiveness of an anti- parasitic drug in the recovery of moderately ill Covid-19 patients. Novalead is enrolling 100 patients across six centres for the trial which is expected to start in a month’s time.

NovaLead Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

NovaLead Pharma to Conduct Clinical Trials for Repurposed Drug for COVID-19

Lead Product(s): NLP21

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

According to the company, NLP21 shows promising ability to act on COVID-19 through multiple relevant targets which enables its not only to prevent virus binding to the human cells but also clear damaged human cells to allow regeneration of healthier cells.

Cadila Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

COVID-19: AIIMS Bhopal Claims Good Results in Drug Trial

Lead Product(s): Mycobacterium w

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Vaccine

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 16, 2020

Details:

The trials of the drug Mycobacterium W (Mw) were conducted on COVID-19 patients at AIIMS Bhopal for the last few days. If Mycobacterium W proves effective during the clinical trial, it will be used in the treatment of COVID-19.

Cipla

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Gilead Inks Voluntary Licensing Agreements With Multiple Companies for Remdesivir

Lead Product(s): Remdesivir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Gilead Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement May 13, 2020

Details:

The agreements allow the companies – Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan – to manufacture remdesivir for distribution in 127 countries.

Cipla

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Cipal's Clinical Trials Using Arthritis Drug Tocilizumab Get Nod

Lead Product(s): Tocilizumab

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

Tocilizumab has been tested on 6 patients admitted at Seven Hills Hospital and 4 patients in Kasturba Hospital, both COVID-19 centres in Mumbai.

Lupin Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

Chinaplas 2020

Participation Not Confirmed

Update your events

Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis

Lead Product(s): Secnidazole

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

Phase 3 Study of Single-Dose Solosec® demonstrated a clinically and statistically significant response rate, or microbiological cure, in patients dosed with Solosec® as compared to placebo.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

LAXAI Life Sciences

CSIR Seeks Regulatory Nod for Clinical Trials Using Combination of Antivirals and HDTs Against COVID-19

Serum Institute of India

India's Serum Institute to Play Pivotal Role in COVID-19 Vaccines

Bharat Serums & Vaccines ltd

Bharat Serums to assess sepsis drug Ulinastatin for Covid-19

Glenmark

Glenmark to Commence Another New Phase 3 Clinical Trial on a Combination of Two Anti-Viral Drugs Favipiravir and Umifenovir for COVID-19

NovaLead Pharma

Novalead to Start Trial on Anti- Parasitic Drug for Covid-19

NovaLead Pharma

NovaLead Pharma to Conduct Clinical Trials for Repurposed Drug for COVID-19

Cadila Pharmaceuticals

COVID-19: AIIMS Bhopal Claims Good Results in Drug Trial

Cipla

Gilead Inks Voluntary Licensing Agreements With Multiple Companies for Remdesivir

Cipla

Cipal's Clinical Trials Using Arthritis Drug Tocilizumab Get Nod

Lupin Ltd

Lupin Announces Positive Topline Results From its Phase 3 Study of Single-Dose Solosec® (secnidazole) for the Treatment of Trichomoniasis